Treatment adherence (defined as dose delay) ( · adjuvant therapy for early breast cancer
Taxane followed by anthracyclines showed no clear difference in treatment adherence (defined as dose delay) ( compared with anthracyclines followed by taxane (moderate certainty).
1 finding from 1 review
Quality of life ( · adjuvant therapy for early breast cancer
1 finding from 1 review
Disease-free survival · neoadjuvant therapy for early breast cancer
Taxane followed by anthracyclines showed no clear difference in disease‐free survival ( compared with anthracyclines followed by taxane (moderate certainty).
1 finding from 1 review
Pathological complete response · neoadjuvant therapy for early breast cancer
Taxane followed by anthracyclines showed no clear difference in pathological complete response (no invasive cancer in breast or… compared with anthracyclines followed by taxane (high certainty).
1 finding from 1 review
Grade 3 to 4 neutropenia · neoadjuvant therapy for early breast cancer
Taxane followed by anthracyclines showed no clear difference in adverse events: neutropenia (grade 3/4) ( compared with anthracyclines followed by taxane (moderate certainty).
1 finding from 1 review
Adverse events: neurotoxicity (grade 3/4) ( · neoadjuvant therapy for early breast cancer
Taxane followed by anthracyclines showed no clear difference in adverse events: neurotoxicity (grade 3/4) ( compared with anthracyclines followed by taxane (low certainty).
1 finding from 1 review
Treatment adherence (defined as dose reduction) ( · neoadjuvant therapy for early breast cancer
Taxane followed by anthracyclines showed no clear difference in treatment adherence (defined as dose reduction) ( compared with anthracyclines followed by taxane (moderate certainty).
1 finding from 1 review
Quality of life · neoadjuvant therapy for early breast cancer
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Overall survival · adjuvant therapy for early breast cancer
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Disease-free survival · adjuvant therapy for early breast cancer
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Overall survival (survival until death from all causes) · adult women diagnosed with early stage (I to IIa) endometrial cancer undergoing surgery as primary treatment.
Laparoscopy showed no clear difference in overall survival (survival until death from all causes) compared with laparotomy (moderate certainty).
1 finding from 1 review
Recurrence‐free survival · adult women diagnosed with early stage (I to IIa) endometrial cancer undergoing surgery as primary treatment.
Laparoscopy showed no clear difference in recurrence free survival compared with laparotomy (moderate certainty).
1 finding from 1 review
Serious adverse events (range of outcomes) · adult women diagnosed with early stage (I to IIa) endometrial cancer undergoing surgery as primary treatment.
Laparoscopy showed no clear difference in serious adverse events (range of outcomes) compared with laparotomy (low certainty).
1 finding from 1 review
All‐cause mortality · Patients with early unfavourable or advanced stage HL
Escalated BEACOPP leads to lower mortality compared with chemotherapy including ABVD (high certainty).
1 finding from 1 review
Relapse, progression or death (calculated instead of PFS) · Patients with early unfavourable or advanced stage HL
Escalated BEACOPP probably leads to lower progression, relapse or death compared with chemotherapy including ABVD (moderate certainty).
1 finding from 1 review
Adverse event: treatment‐related mortality · Patients with early unfavourable or advanced stage HL
Escalated BEACOPP showed no clear difference in adverse event: treatment‐related mortality compared with chemotherapy including ABVD (low certainty).
1 finding from 1 review
Adverse event: secondary malignancies · Patients with early unfavourable or advanced stage HL
Escalated BEACOPP showed no clear difference in adverse event: secondary malignancies compared with chemotherapy including ABVD (low certainty).
1 finding from 1 review
Adverse event: secondary malignancies: AML or MDS · Patients with early unfavourable or advanced stage HL
Escalated BEACOPP may leads to higher adverse event: secondary malignancies: AML or MDS compared with chemotherapy including ABVD (low certainty).
1 finding from 1 review
Adverse event: infertility (secondary amenorrhoea) · Patients with early unfavourable or advanced stage HL
It is very uncertain whether escalated BEACOPP changes adverse event: infertility (secondary amenorrhoea) compared with chemotherapy including ABVD (very low certainty).
1 finding from 1 review
Quality of life · Patients with early unfavourable or advanced stage HL
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found